Part 1: CUTV News Radio welcomes back Dr. David Elmaleh of AZTherapies

Boston, MA – Dr. David Elmaleh is the founder and chairman of AZTherapies, an advanced clinical stage pharmaceutical company dedicated to developing breakthrough treatments for Alzheimer’s disease, ischemic stroke, ALS and other neurological diseases associated with neuroinflammation and neurodegeneration.

“The big companies are trying to find cures,” says Dr. Elmaleh. “Our program is very different. What if we can improve quality of life by extending normal function of people prone to neurodegeneration onset for as long as possible?

AZTherapies stands at the forefront of the discovery, development, and commercialization of revolutionary therapeutics that will fundamentally improve patient treatment, quality of life and disease management. Their innovative drug combination approach seeks to address the neuroinflammation response associated with neurodegeneration and Alzheimer’s disease, as well as slowing down neural network due to plaque and tangles deposit.

The lead product candidate, a combination multi-faceted treatment using two re-engineered drugs, cromolyn and ibuprofen, with novel physical and delivery properties, IP protected, ALZT-OP1, is being studied in a Phase 3 Early Alzheimer’s clinical trial, the COGNITE trial. AZTherapies uses strict inclusion criteria for cognition and function and CSF biomarkers to increase the accuracy of early AD diagnosis and homogeneity of the randomized subjects for the COGNITE Trial.”

“Many scientists are expressing the opinion that they’re going to increase life for 200 years, realistically, there is no cure for aging. We can’t stop it,” says Dr. Elmaleh. “So it’s about the quality of life, not the quantity of year.”

For more information on AZTherapies, visit www.aztherapies.com